Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Corbus Pharmaceuticals (CRBP) shares fell 6.98% to $9.46 on Monday, underperforming competitors like Vanda and Fortress Biotech which saw gains. The decline ended a four-day winning streak and occurred amidst a broader market dip. Trading volume was below the 50-day average. CRBP remains significantly below its 52-week high.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) shed 6.98% to $9.46 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 0.32% to 26,605.36 and Dow Jones Industrial Average falling 0.11% to 53,975.98.
The stock's fall snapped a four-day winning streak.
Corbus Pharmaceuticals Holdings Inc. closed 53.99% below its 52-week high of $20.56, which the company achieved on October 20th.
The stock underperformed when compared to some of its competitors Monday, as Vanda Pharmaceuticals Inc. (VNDA) rose 0.40% to $5.02, Fortress Biotech Inc. (FBIO) rose 3.00% to $2.75, and Viking Therapeutics Inc. (VKTX) rose 0.53% to $34.44.
Trading volume (335,694) remained 76,998 below its 50-day average volume of 412,692.
Data source: Dow Jones Market Data, FactSet. Data compiled August 10, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-10-26 1722ET